Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.
Tessari A, Parbhoo K, Pawlikowski M, Fassan M, Rulli E, Foray C, Fabbri A, Embrione V, Ganzinelli M, Capece M, Campbell MJ, Broggini M, La Perle K, Farina G, Cole S, Marabese M, Hernandez M, Amann JM, Pruneri G, Carbone DP, Garassino MC, Croce CM, Palmieri D, Coppola V. Tessari A, et al. Among authors: garassino mc. Oncogene. 2018 Dec;37(50):6463-6476. doi: 10.1038/s41388-018-0424-8. Epub 2018 Aug 3. Oncogene. 2018. PMID: 30076413 Free PMC article.
Response of thymoma to cetuximab.
Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G, Scanni A. Farina G, et al. Among authors: garassino mc. Lancet Oncol. 2007 May;8(5):449-50. doi: 10.1016/S1470-2045(07)70141-9. Lancet Oncol. 2007. PMID: 17466903 No abstract available.
Maintenance therapy in NSCLC: why? To whom? Which agent?
Novello S, Milella M, Tiseo M, Banna G, Cortinovis D, Di Maio M, Garassino M, Maione P, Martelli O, Vavalà T, Bria E. Novello S, et al. J Exp Clin Cancer Res. 2011 May 6;30(1):50. doi: 10.1186/1756-9966-30-50. J Exp Clin Cancer Res. 2011. PMID: 21548925 Free PMC article. Review.
Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
Pelosi G, Haspinger ER, Bimbatti M, Leone G, Paolini B, Fabbri A, Tamborini E, Perrone F, Testi A, Garassino M, Maisonneuve P, de Braud F, Pilotti S, Pastorino U. Pelosi G, et al. Int J Surg Pathol. 2014 Apr;22(2):136-48. doi: 10.1177/1066896913511527. Epub 2013 Dec 9. Int J Surg Pathol. 2014. PMID: 24326823
Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
Pelosi G, Fabbri A, Papotti M, Rossi G, Cavazza A, Righi L, Tamborini E, Perrone F, Settanni G, Busico A, Testi MA, Maisonneuve P, De Braud F, Garassino M, Valeri B, Sonzogni A, Pastorino U. Pelosi G, et al. J Thorac Oncol. 2015 Nov;10(11):1560-9. doi: 10.1097/JTO.0000000000000658. J Thorac Oncol. 2015. PMID: 26317919 Free article.
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
Marabese M, Ganzinelli M, Garassino MC, Shepherd FA, Piva S, Caiola E, Macerelli M, Bettini A, Lauricella C, Floriani I, Farina G, Longo F, Bonomi L, Fabbri MA, Veronese S, Marsoni S, Broggini M, Rulli E. Marabese M, et al. Among authors: garassino mc. Oncotarget. 2015 Oct 20;6(32):34014-22. doi: 10.18632/oncotarget.5607. Oncotarget. 2015. PMID: 26416458 Free PMC article. Clinical Trial.
247 results